TY - JOUR

T1 - Aromatase Inhibitor–Related Symptoms Reported by Postmenopausal Women with Nonmetastatic, Estrogen Receptor–Positive Breast Cancer

T2 - A Systematic Review

AU - Lund-Jacobsen, Trine

AU - Bentsen, Line

AU - Schwarz, Peter

AU - Knop, Ann Søegaard

AU - Pappot, Helle

AU - Piil, Karin

N1 - Publisher Copyright: © 2023 The Authors

PY - 2023

Y1 - 2023

N2 - Purpose: The objective of this systematic review was to establish an overview of aromatase inhibitor–related symptoms reported by postmenopausal women with nonmetastatic, estrogen receptor–positive breast cancer. Data Sources: Eight databases (PubMed, Cochrane, Cumulative Index to Nursing and Allied Health Literature [CINAHL], Ovid EMBASE, Ovid MEDLINE, PsycINFO, Scopus, and Web of Science) were searched for trials published between January 2004 and November 2021. Inclusion criteria were studies exploring patient-reported aromatase inhibitor–related symptoms in postmenopausal women with nonmetastatic estrogen receptor–positive breast cancer. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Mixed Method Appraisal Tool were used to rate the quality of the trials included. Of 325 full-text papers, 10 were included. Patient-reported symptoms were clustered by using the European Organization for Research and Treatment of Cancer Quality of Life C30 questionnaire domains. Additional domains were used to cluster other symptoms mentioned: menopausal, sex-related, body alteration, and eye-related. The following clusters were the most frequently presented: sex-related (14 symptoms), pain (9 symptoms), insomnia (5 symptoms), and menopausal (5 symptoms). Conclusion: The target group reported a variety of symptoms related to aromatase inhibitors. No tools are currently available to measure all the symptoms reported, indicating a need to revise the tools to acknowledge additional symptoms. Prospective studies are needed to investigate the prevalence of aromatase inhibitor–related symptoms in women with breast cancer. Implication for Nursing Practice: Identification of patient-reported clinically relevant symptoms can enable targeted symptom assessment and management strategies for women with breast cancer undergoing aromatase inhibitor treatment.

AB - Purpose: The objective of this systematic review was to establish an overview of aromatase inhibitor–related symptoms reported by postmenopausal women with nonmetastatic, estrogen receptor–positive breast cancer. Data Sources: Eight databases (PubMed, Cochrane, Cumulative Index to Nursing and Allied Health Literature [CINAHL], Ovid EMBASE, Ovid MEDLINE, PsycINFO, Scopus, and Web of Science) were searched for trials published between January 2004 and November 2021. Inclusion criteria were studies exploring patient-reported aromatase inhibitor–related symptoms in postmenopausal women with nonmetastatic estrogen receptor–positive breast cancer. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Mixed Method Appraisal Tool were used to rate the quality of the trials included. Of 325 full-text papers, 10 were included. Patient-reported symptoms were clustered by using the European Organization for Research and Treatment of Cancer Quality of Life C30 questionnaire domains. Additional domains were used to cluster other symptoms mentioned: menopausal, sex-related, body alteration, and eye-related. The following clusters were the most frequently presented: sex-related (14 symptoms), pain (9 symptoms), insomnia (5 symptoms), and menopausal (5 symptoms). Conclusion: The target group reported a variety of symptoms related to aromatase inhibitors. No tools are currently available to measure all the symptoms reported, indicating a need to revise the tools to acknowledge additional symptoms. Prospective studies are needed to investigate the prevalence of aromatase inhibitor–related symptoms in women with breast cancer. Implication for Nursing Practice: Identification of patient-reported clinically relevant symptoms can enable targeted symptom assessment and management strategies for women with breast cancer undergoing aromatase inhibitor treatment.

KW - Aromatase inhibitors

KW - Breast cancer

KW - EORTC QLQ-C30

KW - Health-related quality of life

KW - Patient-reported symptoms

KW - Symptom management

U2 - 10.1016/j.soncn.2023.151487

DO - 10.1016/j.soncn.2023.151487

M3 - Review

C2 - 37612223

AN - SCOPUS:85168627408

VL - 39

JO - Seminars in Oncology Nursing

JF - Seminars in Oncology Nursing

SN - 0749-2081

IS - 5

M1 - 151487

ER -